SPOTLIGHT: PerkinElmer paying $300M for ViaCell

PerkinElmer is buying ViaCell for $300 million, aiming to grow the latter's cord-blood banking business and spin off its drug-discovery unit, which is working on stem-cell-based remedies for cancer, heart disease, and diabetes. Release

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.